US2020071328A1PendingUtilityA1
1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
Est. expiryAug 25, 2032(~6.1 yrs left)· nominal 20-yr term from priority
Inventors:Vijaykumar Jagdishwar PatilRavikumar TadiparthiBharat DondAmol KaleLoganathan VelupillaiDeepak DekhaneSatish BirajdarMohammad Usman ShaikhSushilkumar MauryaPiyush Ambalal PatelPrasad DixitMangesh PawarMahesh Vithalbhai PatelSachin Bhagwat
A61K 31/4545C07C 211/63A61K 31/55A61K 31/439A61K 9/0053C07D 487/08C07D 471/08A61K 31/496A61K 9/20A61K 31/546A61K 45/06A61P 31/04A61K 9/48A61K 31/407
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition, comprising: (a) at least one antibacterial agent independently selected from cefpodoxime, ceftibuten, cefuroxime, cefixime and pharmaceutically acceptable salts thereof; and (b) at least one compound independently selected from:
and
stereoisomers and pharmaceutically acceptable salts thereof.
2 . The pharmaceutical composition of claim 1 , further comprising at least one pharmaceutically acceptable excipient.
3 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefpodoxime or a pharmaceutically acceptable salt thereof.
4 . The pharmaceutical composition of claim 3 , wherein the cefpodoxime is cefpodoxime axetil.
5 . The pharmaceutical composition of claim 3 , wherein the cefpodoxime is cefpodoxime proxetil.
6 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is ceftibuten or a pharmaceutically acceptable salt thereof.
7 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefuroxime or a pharmaceutically acceptable salt thereof.
8 . The pharmaceutical composition of claim 7 , where the cefuroxime is cefuroxime axetil.
9 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefiximeor a pharmaceutically acceptable salt thereof.
10 . The pharmaceutical composition of claim 1 , wherein the at least one compound is in the form of a sodium salt.
11 . The pharmaceutical composition of claim 1 , wherein the at least one compound is
or a stereoisomer or pharmaceutically acceptable salt thereof.
12 . The pharmaceutical composition of claim 1 , wherein the at least one compound is
or a stereoisomer or pharmaceutically acceptable salt thereof.
13 . The pharmaceutical composition of claim 1 , wherein the at least one compound is
or a stereoisomer or pharmaceutically acceptable salt thereof.
14 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefpodoxime, and the at least one compound is
15 . The pharmaceutical composition of claim 14 , wherein the cefpodoxime is cefpodoxime axetil.
16 . The pharmaceutical composition of claim 14 , wherein the cefpodoxime is cefpodoxime proxetil.
17 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is ceftibuten, and the at least one compound is
18 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefuroxime, and the at least one compound is
19 . The pharmaceutical composition of claim 18 , wherein the cefuroxime is cefuroxime axetil.
20 . The pharmaceutical composition of claim 1 , wherein the at least one antibacterial agent is cefixime, and the at least one compound isCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.